ACAD

16.37

1.17% 0.19

Handel nachbörslich: 16.40 0.03 +0.18%

Acadia Pharmaceuticals Inc (ACAD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ACAD? Forum Prognose

Schlusskurs vom Vortag:

$16.18

Offen:

$16.15

24-Stunden-Volumen:

1.36M

Relative Volume:

1.04

Marktkapitalisierung:

$2.72B

Einnahmen:

$890.53M

Nettoeinkommen (Verlust:

$30.57M

KGV:

-17.79

EPS:

-0.92

Netto-Cashflow:

$80.53M

1W Leistung:

-2.39%

1M Leistung:

+12.74%

6M Leistung:

+3.48%

1J Leistung:

-25.56%

1-Tages-Spanne:

$16.01

$16.69

1-Wochen-Bereich:

$15.66

$17.17

52-Wochen-Spanne:

$14.15

$32.59

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Firmenname

Acadia Pharmaceuticals Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

858-558-2871

Adresse

12830 EL CAMINO REAL, SAN DIEGO

Mitarbeiter

620

Twitter

@acadiapharma

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

ACAD's Discussions on Twitter

Vergleichen Sie ACAD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACAD	16.37	2.72B	890.53M	30.57M	80.53M	-0.92
VRTX	450.97	116.14B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	81.10B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.23B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.12B	3.30B	-501.07M	1.03B	11.54

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-03-12	Herabstufung	Mizuho	Buy → Neutral
2024-03-12	Bestätigt	Needham	Buy
2024-01-30	Eingeleitet	Robert W. Baird	Outperform
2024-01-24	Hochstufung	Needham	Hold → Buy
2023-12-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-12-14	Herabstufung	Deutsche Bank	Buy → Hold
2023-12-13	Eingeleitet	Citigroup	Buy
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-11-06	Hochstufung	Mizuho	Neutral → Buy
2023-10-17	Eingeleitet	UBS	Buy
2023-10-10	Hochstufung	JP Morgan	Neutral → Overweight
2023-01-03	Hochstufung	Guggenheim	Neutral → Buy
2022-11-04	Herabstufung	Goldman	Neutral → Sell
2022-11-01	Eingeleitet	Loop Capital	Hold
2022-08-08	Herabstufung	Citigroup	Buy → Neutral
2022-08-05	Herabstufung	Citigroup	Buy → Neutral
2022-06-21	Herabstufung	Jefferies	Buy → Underperform
2022-06-16	Hochstufung	Jefferies	Hold → Buy
2022-03-16	Hochstufung	Canaccord Genuity	Hold → Buy
2022-02-09	Hochstufung	H.C. Wainwright	Neutral → Buy
2022-01-05	Hochstufung	Citigroup	Neutral → Buy
2021-12-21	Herabstufung	Guggenheim	Buy → Neutral
2021-11-01	Hochstufung	Guggenheim	Neutral → Buy
2021-10-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Fortgesetzt	Needham	Hold
2021-06-10	Eingeleitet	Berenberg	Hold
2021-04-07	Herabstufung	H.C. Wainwright	Buy → Neutral
2021-04-06	Herabstufung	Canaccord Genuity	Buy → Hold
2021-04-06	Herabstufung	Goldman	Buy → Neutral
2021-04-06	Herabstufung	Jefferies	Buy → Hold
2021-04-06	Herabstufung	Mizuho	Buy → Neutral
2021-04-05	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-03-10	Herabstufung	BofA Securities	Buy → Neutral
2021-03-09	Herabstufung	Citigroup	Buy → Neutral
2021-03-09	Herabstufung	Guggenheim	Buy → Neutral
2021-03-09	Bestätigt	H.C. Wainwright	Buy
2021-03-09	Herabstufung	Raymond James	Strong Buy → Outperform
2021-03-09	Herabstufung	Stifel	Buy → Hold
2020-12-16	Eingeleitet	Mizuho	Buy
2020-11-16	Hochstufung	Raymond James	Outperform → Strong Buy
2020-08-25	Eingeleitet	Raymond James	Outperform
2020-08-20	Eingeleitet	Morgan Stanley	Overweight
2020-07-07	Hochstufung	Stifel	Hold → Buy
2020-04-16	Eingeleitet	Jefferies	Buy
2020-03-31	Hochstufung	Goldman	Neutral → Buy
2020-03-06	Eingeleitet	Citigroup	Buy
2019-12-16	Eingeleitet	Guggenheim	Buy
2019-10-24	Eingeleitet	Oppenheimer	Perform
2019-10-01	Eingeleitet	RBC Capital Mkts	Outperform
2019-09-13	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-09-10	Hochstufung	Canaccord Genuity	Hold → Buy
2019-07-23	Bestätigt	Needham	Buy
2018-12-10	Eingeleitet	Canaccord Genuity	Hold
2018-09-21	Hochstufung	Piper Jaffray	Neutral → Overweight
2018-08-09	Bestätigt	Stifel	Hold
2018-08-07	Eingeleitet	Stifel	Hold
2018-08-06	Herabstufung	Piper Jaffray	Overweight → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten

03:16 AM

Principal Financial Group Inc. Acquires 52,340 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

03:16 AM

Nov 21, 2024

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - The Bakersfield Californian

Nov 21, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Decreased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat

Nov 21, 2024

When (ACAD) Moves Investors should Listen - Stock Traders Daily

Nov 21, 2024

Nov 20, 2024

Acadia Pharmaceuticals announces executive shakeup - Investing.com

Nov 20, 2024

Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without Cause - MarketWatch

Nov 20, 2024

Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure - TipRanks

Nov 20, 2024

Acadia Pharmaceuticals announces executive shakeup By Investing.com - Investing.com UK

Nov 20, 2024

Acadia Pharma (ACAD) Chief Operating Officer to be Involuntarily Terminated Without Cause - StreetInsider.com

Nov 20, 2024

Acadia Pharma ticks lower amid Deutsche Bank downgrade after surge on patent win - MSN

Nov 20, 2024

Acadia Pharmaceuticals CFO sells shares worth $172,453 By Investing.com - Investing.com Canada

Nov 19, 2024

Acadia Pharmaceuticals' COO sells $173,630 in stock By Investing.com - Investing.com Canada

Nov 19, 2024

FY2024 Earnings Estimate for ACAD Issued By Leerink Partnrs - MarketBeat

Nov 19, 2024

Nov 16, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Lowered by GSA Capital Partners LLP - MarketBeat

Nov 16, 2024

Nov 15, 2024

Acadia Pharmaceuticals Grants Stock Options, RSUs to 23 New Employees in Growth Push | ACAD Stock News - StockTitan

Nov 15, 2024

Nov 13, 2024

ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock By Investing.com - Investing.com Canada

Nov 13, 2024

ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com

Nov 13, 2024

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat

Nov 13, 2024

Nov 12, 2024

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance

Nov 12, 2024

US Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Acadia Pharmaceuticals: Proving The Naysayers Wrong (NASDAQ:ACAD) - Seeking Alpha

Nov 11, 2024

What is Leerink Partnrs' Forecast for ACAD FY2026 Earnings? - MarketBeat

Nov 11, 2024

FY2024 Earnings Estimate for ACAD Issued By HC Wainwright - MarketBeat

Nov 11, 2024

Nov 10, 2024

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates - MSN

Nov 10, 2024

Nov 09, 2024

ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Acadia Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for ACAD - Nasdaq

Nov 08, 2024

Acadia Pharmaceuticals price target lowered to $32 from $33 at Canaccord - TipRanks

Nov 08, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Equities Analysts Issue Forecasts for ACAD FY2027 Earnings - MarketBeat

Nov 08, 2024

HC Wainwright Issues Pessimistic Estimate for ACAD Earnings - MarketBeat

Nov 08, 2024

ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St

Nov 08, 2024

ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024